PDF(Pubmed)
Abstract：
Voriconazole is a second-generation azole widely used for the prevention and treatment of fungal infection in leukemia patients. We report a case of 9-year-old girl with T-cell acute lymphoblastic leukemia who developed hallucinations and visual disturbance after using voriconazole twice. These symptoms began acutely after treatment with voriconazole and resolved rapidly when the voriconazole was stopped. No specific cause was identified, and thus the symptoms were considered to be the adverse drug reactions (ADRs) of voriconazole. Simultaneous development of hallucinations and visual disturbance caused by voriconazole in children rarely have been reported before and the causes of these ADRs are unknown. Several other cases of hallucinations and (or) visual disturbance caused by voriconazole among 15-81 years old patients have been reported in the literature, and are reviewed. Those patients reminded us of the importance of being aware of hallucinations and visual disturbance associated with voriconazole treatment. In addition, we speculate that the hallucinations and visual disturbance are not related to the dosage form of voriconazole. We emphasize that it is also important to monitor the concentration of voriconazole regularly to avoid potential toxicity.
摘要：
伏立康唑是一种第二代唑，广泛用于预防和治疗白血病患者的真菌感染。我们报告了一例9岁的T细胞急性淋巴细胞白血病女孩，该女孩在两次使用伏立康唑后出现幻觉和视力障碍。这些症状在使用伏立康唑治疗后急剧开始，并在停用伏立康唑时迅速缓解。没有确定具体原因，因此，症状被认为是伏立康唑的药物不良反应（ADR）。以前很少报道过伏立康唑在儿童中同时出现幻觉和视觉障碍，并且这些ADR的原因尚不清楚。文献中报道了其他几例由伏立康唑引起的幻觉和（或）视觉障碍在15-81岁的患者中，并进行了审查。这些患者提醒我们意识到与伏立康唑治疗相关的幻觉和视觉障碍的重要性。此外,我们推测幻觉和视觉障碍与伏立康唑的剂型无关。我们强调定期监测伏立康唑的浓度以避免潜在的毒性也很重要。
